PI3K isoform-selective inhibitors in cancer

Leslie Duncan, Chloe Shay, Yong Teng

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

PI3K inhibitors are a common area of research in finding a successful treatment of cancer. The PI3K pathway is important for cell growth, apoptosis, cell metabolism, cell survival, and a multitude of other functions. There are multiple isoforms of PI3K that can be broken down into three categories: class I, II, and III. Each isoform has at least one subunit that helps with the functionality of the isoform. Mutations found in the PI3K isoforms are commonly seen in many different types of cancer and the use of inhibitors is being tested to stop the cell survival of cancer cells. Individual PI3K inhibitors have shown some inhibition of the pathway; however, there is room for improvement. To better treat cancer, PI3K inhibitors are being combined with other pathway inhibitors. These combination therapies have shown better results with cancer treatments. Both the monotherapy and dual therapy treatments are still currently being studied and data collected to better understand cancer and other treatment options.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer
Pages165-173
Number of pages9
DOIs
StatePublished - 2020

Publication series

NameAdvances in Experimental Medicine and Biology
Volume1255
ISSN (Print)0065-2598
ISSN (Electronic)2214-8019

Keywords

  • Anticancer
  • Cancer
  • Inhibitor
  • Isoforms
  • Mutations
  • PI3K

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'PI3K isoform-selective inhibitors in cancer'. Together they form a unique fingerprint.

Cite this